Submission to Australia's National Medicines Policy Review

The 2021 WHO Essential Medicines List: How Pharma Can Turn Challenge into Opportunity

Medicines Australia Strategic Agreement is 'the end of the beginning'

NICE methods review, UK Life Sciences Strategy and the life sciences industry: lessons for Australia

Workers of the world resign!: What if post-pandemic staff refuse to return to the office?

Reaching the sea, the sun and the end - Day 7 C2K

Dust, stars and crocodiles – Days 5 & 6 C2K

The roads, the dust and the crash - days 3 & 4 C2K

Dodgy eyes, taipans and a COVID moment - days 1 & 2 C2K

Stroking my ageing ego: pre-ride training for the C2K

Fair dinkum or collywobbles? Life sciences and the Australia – UK free trade agreement

Opportunities for the Life Science Industry in Australia post-COVID

More risk for government this time around in agreement negotiation

It's just the vibe: soft skills in the art of government-business relations

Ethics own goal in opioid epidemic: the role of consultants

5 Trends for Life Science Companies to Watch in 2021

Submission to Australian House of Representatives inquiry into approval processes for new drugs

‘Roll with the punches and get to what’s real’: reflections on 2020

COVID-19 vaccination a 12-month success for science, governments and industry

A little less conversation, a little more action please: the global state of AMR